Indulekha Breakthrough: Hair Growth Serum Delivers Stunning Results in Latest Cl
Indulekha has successfully concluded its second large-scale clinical study on the Indulekha Bringha Hair Growth Serum, a significant milestone in the company's ongoing commitment to rigorous scientific testing.
Key takeaways from the latest research studies, conducted in 2025 and following an initial investigation in 2024:
- A remarkable 11,000 new hair strands were observed to grow within a 90-day period, as confirmed through a thorough scientific analysis.
- The serum demonstrated the ability to promote twice as much hair growth compared to products containing 3% Redensyl.
- A significant 74% improvement in the Anagen-to-Telogen (A:T) ratio was observed, underscoring the product's capacity to restore a healthier hair growth cycle.
The clinical studies were conducted by registered Clinical Research Organisations under the supervision of dermatologists and Ayurvedic practitioners, ensuring the highest standards of scientific integrity.
“Our approach combines authentic Ayurvedic formulations with rigorous clinical validation. By conducting two independent trials across two years, we strive to provide consumers with transparency and confidence in the product's efficacy and its ability to deliver tangible results,” said Sairam Subramanian, VP, Haircare, Unilever.
The research findings indicate that the formulation supports natural hair growth by delivering measurable outcomes at a follicular level. It was also noted that 97% of participants reported an increase in thickness and visibly improved hair volume.
Given the numerous products available in the scalp serum category, it was essential to rigorously evaluate the efficacy of 3% Redensyl through comparative clinical studies against Indulekha Hair Growth Serum, providing a science-backed assessment of performance.
The dual trials involved participants aged between 20 and 45 years, including both men and women experiencing early and moderate hair thinning. Multiple parameters associated with hair growth and scalp health were evaluated, including new hair growth, hair shedding, follicle strength, and scalp barrier function.
Notably, study participants reported strong visible outcomes:
- 100% observed thicker-looking hair
- 97% reported a noticeable reduction in hair fall
- 97% experienced improvement in hair density
The findings from the 2024 clinical trial have already been published, while the 2025 trial results are pending publication in the International Journal of Research in Dermatology.
To ensure relevance and applicability to local scalp characteristics and hair density, Indulekha conducts ongoing clinical trials on Indian participants experiencing hair fall. The brand relies on scientific validation for its products through rigorous testing.
Note: This article is part of Hindustan Times' promotional consumer connect initiative and is independently created by the brand. Hindustan Times assumes no editorial responsibility for the content.
Rubenhair Clinic - Hair Transplant in Latvia. Learn more about our hair transplant services.